Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer

Hajime Otsu, Eiji Oki, Ayae Ikawa-Yoshida, Hiroyuki Kawano, Koji Ando, Satoshi Ida, Yasue Kimura, Shinichi Aishima, Hiroshi Saeki, Masaru Morita, Shunji Kohnoe, Yoshinao Oda, Yoshihiko Maehara

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Results from the Trastuzumab for Gastric Cancer (ToGA) trial highlighted the clinical significance of trastuzumab in the treatment of HER2 (Human Epidermal Growth Factor Receptor type 2)-positive gastric cancer. However, whether expression of HER2 is related to prognosis of gastric cancer is still controversial. A total of 360 consecutive patients with gastric cancer who underwent surgical resection in our Department from 1994 to 2007 were analyzed. We performed immunohistochemical analysis of HER2 expression. HER2 expression level was classified into four scores (0, 1+, 2+ and 3+). There were 37 (10%) patients with a score of 3+. A score of 3+ was defined as being HER2-positive. Recurrence-free survival was worse in HER2-positive cases (p=0.045). When the analysis was conducted with intestinal types of cancer, RFS was considerably worse in the HER2-positive group (p=0.011). HER2 expression may have potential as a prognostic factor for intestinal cancer types. Further research is warranted.

Original languageEnglish
Pages (from-to)2441-2446
Number of pages6
JournalAnticancer research
Volume35
Issue number4
Publication statusPublished - Apr 1 2015

Fingerprint

Stomach Neoplasms
Intestinal Neoplasms
Clinical Trials
Recurrence
Survival
Research
Trastuzumab
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer. / Otsu, Hajime; Oki, Eiji; Ikawa-Yoshida, Ayae; Kawano, Hiroyuki; Ando, Koji; Ida, Satoshi; Kimura, Yasue; Aishima, Shinichi; Saeki, Hiroshi; Morita, Masaru; Kohnoe, Shunji; Oda, Yoshinao; Maehara, Yoshihiko.

In: Anticancer research, Vol. 35, No. 4, 01.04.2015, p. 2441-2446.

Research output: Contribution to journalArticle

Otsu, H, Oki, E, Ikawa-Yoshida, A, Kawano, H, Ando, K, Ida, S, Kimura, Y, Aishima, S, Saeki, H, Morita, M, Kohnoe, S, Oda, Y & Maehara, Y 2015, 'Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer', Anticancer research, vol. 35, no. 4, pp. 2441-2446.
Otsu, Hajime ; Oki, Eiji ; Ikawa-Yoshida, Ayae ; Kawano, Hiroyuki ; Ando, Koji ; Ida, Satoshi ; Kimura, Yasue ; Aishima, Shinichi ; Saeki, Hiroshi ; Morita, Masaru ; Kohnoe, Shunji ; Oda, Yoshinao ; Maehara, Yoshihiko. / Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer. In: Anticancer research. 2015 ; Vol. 35, No. 4. pp. 2441-2446.
@article{fabef753bbb943ba8c59fb43cfd04f16,
title = "Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer",
abstract = "Results from the Trastuzumab for Gastric Cancer (ToGA) trial highlighted the clinical significance of trastuzumab in the treatment of HER2 (Human Epidermal Growth Factor Receptor type 2)-positive gastric cancer. However, whether expression of HER2 is related to prognosis of gastric cancer is still controversial. A total of 360 consecutive patients with gastric cancer who underwent surgical resection in our Department from 1994 to 2007 were analyzed. We performed immunohistochemical analysis of HER2 expression. HER2 expression level was classified into four scores (0, 1+, 2+ and 3+). There were 37 (10{\%}) patients with a score of 3+. A score of 3+ was defined as being HER2-positive. Recurrence-free survival was worse in HER2-positive cases (p=0.045). When the analysis was conducted with intestinal types of cancer, RFS was considerably worse in the HER2-positive group (p=0.011). HER2 expression may have potential as a prognostic factor for intestinal cancer types. Further research is warranted.",
author = "Hajime Otsu and Eiji Oki and Ayae Ikawa-Yoshida and Hiroyuki Kawano and Koji Ando and Satoshi Ida and Yasue Kimura and Shinichi Aishima and Hiroshi Saeki and Masaru Morita and Shunji Kohnoe and Yoshinao Oda and Yoshihiko Maehara",
year = "2015",
month = "4",
day = "1",
language = "English",
volume = "35",
pages = "2441--2446",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer

AU - Otsu, Hajime

AU - Oki, Eiji

AU - Ikawa-Yoshida, Ayae

AU - Kawano, Hiroyuki

AU - Ando, Koji

AU - Ida, Satoshi

AU - Kimura, Yasue

AU - Aishima, Shinichi

AU - Saeki, Hiroshi

AU - Morita, Masaru

AU - Kohnoe, Shunji

AU - Oda, Yoshinao

AU - Maehara, Yoshihiko

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Results from the Trastuzumab for Gastric Cancer (ToGA) trial highlighted the clinical significance of trastuzumab in the treatment of HER2 (Human Epidermal Growth Factor Receptor type 2)-positive gastric cancer. However, whether expression of HER2 is related to prognosis of gastric cancer is still controversial. A total of 360 consecutive patients with gastric cancer who underwent surgical resection in our Department from 1994 to 2007 were analyzed. We performed immunohistochemical analysis of HER2 expression. HER2 expression level was classified into four scores (0, 1+, 2+ and 3+). There were 37 (10%) patients with a score of 3+. A score of 3+ was defined as being HER2-positive. Recurrence-free survival was worse in HER2-positive cases (p=0.045). When the analysis was conducted with intestinal types of cancer, RFS was considerably worse in the HER2-positive group (p=0.011). HER2 expression may have potential as a prognostic factor for intestinal cancer types. Further research is warranted.

AB - Results from the Trastuzumab for Gastric Cancer (ToGA) trial highlighted the clinical significance of trastuzumab in the treatment of HER2 (Human Epidermal Growth Factor Receptor type 2)-positive gastric cancer. However, whether expression of HER2 is related to prognosis of gastric cancer is still controversial. A total of 360 consecutive patients with gastric cancer who underwent surgical resection in our Department from 1994 to 2007 were analyzed. We performed immunohistochemical analysis of HER2 expression. HER2 expression level was classified into four scores (0, 1+, 2+ and 3+). There were 37 (10%) patients with a score of 3+. A score of 3+ was defined as being HER2-positive. Recurrence-free survival was worse in HER2-positive cases (p=0.045). When the analysis was conducted with intestinal types of cancer, RFS was considerably worse in the HER2-positive group (p=0.011). HER2 expression may have potential as a prognostic factor for intestinal cancer types. Further research is warranted.

UR - http://www.scopus.com/inward/record.url?scp=84928380294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928380294&partnerID=8YFLogxK

M3 - Article

C2 - 25862912

AN - SCOPUS:84928380294

VL - 35

SP - 2441

EP - 2446

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -